Log inLog out
Report
This is a proof-of-concept page demonstrating how large language models can build and maintain a research database. It has not been audited by a human, may contain errors, and must not be relied upon for accuracy. Use at your own risk — this is not investment advice and must not be used for investment purposes.

Colgate-Palmolive Company

From ReportWarehouse, the free investment-report repository

Colgate-Palmolive Company is an American consumer products company that manufactures and markets oral care, personal care, home care, and pet nutrition products sold in over 200 countries and territories worldwide, generating $20.38 billion in revenue in fiscal 2025. Founded in 1806 and incorporated in 1923, the company holds the number-one global market share position in toothpaste (41.3%) and manual toothbrushes (32.7%), operates the Hill's Science Diet and Prescription Diet pet food brands, and has paid a cash dividend every year since 1895 — 63 consecutive years of increases.

This is a story about a 220-year-old compounder navigating a genuinely difficult moment. The business generates prodigious cash flow, dominates categories where brand loyalty and dentist recommendation create genuine moats, and reinvests at high returns. But the FY2025 GAAP numbers mask the story: a $919 million Filorga goodwill impairment pushed reported operating profit down 23%, while organic sales growth slowed to 1.4% and management flagged $300 million in incremental raw-material costs for FY2026 as oil pierced $110. The file turns on a single question: whether Colgate's pricing power, emerging-market footprint, and productivity levers are enough to keep the compounding alive through a period of persistent input-cost inflation and sluggish category growth, or whether the model is beginning to show its age.

The bull case rests on a business that looks better on a non-GAAP basis — operating profit of $4.35 billion (21.3% margin) in FY2025 — and a management team that has moved early on restructuring, announcing a Strategic Growth and Productivity Program in mid-2025 and expanding its savings target to $200–300 million in April 2026. The bear case notes that Colgate has traded at a premium multiple for decades and that 1.4% organic growth plus compressing GAAP margins does not obviously support a P/E north of 35× trailing earnings. This report sets out to make the reader smarter about which version of the story is more likely.

Full report locked

You are viewing the public summary. The full report — business breakdown, key debates, financials, scenarios, charts and risks — is available to password holders.

Log in to read the full report →

Invitation-only proof of concept. Not investment advice.

Categories: Consumer staplesHousehold & personal productsOral carePet nutritionNYSE-listed companiesDividend aristocrats